newsfilter
← Latest News
GlobeNewswire·

Xenon to Report Q2 2026 Financial Results on August 6, 2026

  • Xenon Pharmaceuticals Inc. (NASDAQ: XENE) will report its second quarter 2026 financial results & provide a business update after the close of U.S. markets on Thursday, August 6, 2026.
  • The company presentation will occur at 4:30pm ET (1:30pm PT) via webcast & dial-in with Conference ID 5286122.
  • The lead molecule azetukalner, a K V 7 potassium channel opener, is in Phase 3 clinical trials for epilepsy, major depressive disorder, & bipolar depression.
  • Xenon is advancing an early-stage portfolio of potassium & sodium channel modulators, including K V 7 & Na V 1.7 programs in Phase 1 for potential pain treatment.
  • The company maintains offices in Vancouver, British Columbia, & Boston, Massachusetts.
  • Investor inquiries should be directed to CFO Tucker Kelly at investors@xenon-pharma.com, while media inquiries go to SVP Colleen Alabiso at media@xenon-pharma.com.